AbbVie Inc. (ABBV)
3 Healthcare Dividend Stocks Offering More Than Just Income
The flight toward dividend-paying stocks is an example of investors taking what the market is giving. In late September, the yield on the 10-year Treasury note climbed above 5%.
BofA Boosts AbbVie and J&J Price Targets on Growth and Pipeline Strength
Bank of America just raised price targets on two pharma giants facing patent cliffs, but its conviction level differs sharply between them, and the valuation gap may explain which one belongs in a long-term portfolio right now.
US FDA approves AbbVie's drug for Parkinson's disease
The US Food and Drug Administration has approved AbbVie's drug for Parkinson's disease in adults, the health regulator's website showed on Friday.
ABBV vs. JNJ: One of These Dividend Aristocrats Will Crush the Other Over the Next Decade
AbbVie and Johnson and Johnson both trade near 52-week highs and carry decades of dividend raises, but one faces a patent cliff and a leveraged balance sheet that could force retirees to rethink their income strategy completely.
2026 2H Healthcare Dividend Roundup: Johnson & Johnson Outshines AbbVie
Johnson & Johnson trades at a 30% P/E premium to AbbVie (24.2x vs. 18.8x on FY1 basis). The premium is further amplified on a PEGY basis (4.80x vs. 2.33x) when yield and growth are factored in. However, JNJ's premium is well justified by its conservative balance sheet and superior capital allocation flexibility.
AbbVie vs. Pfizer: Which Dividend Stock Is the Better Buy in September?
Dividend payments offer you security in difficult markets -- and extra growth in better times. These pharma companies offer dividend yields that beat the dividend yield of the S&P 500.
3 Dividend Stocks to Buy Before September Ends and Hold Forever
With the third quarter closing out, income investors have a narrow window to lock in three cash-generative blue chips before Q3 earnings reset expectations. The shared hook: recession-resilient franchises, multi-decade dividend histories, and reaffirmed or raised 2026 guidance.
5 Stocks, 5 Different Industries, 1 Thing in Common: Reliable Income
A biopharma giant, a chip maker, a delivery network, a trash hauler, and an oncology powerhouse walk into the same portfolio for one reason, and it has nothing to do with chasing the highest yield.
How AbbVie's Neuroscience Portfolio Has Transformed Over the Years
ABBV's neuroscience portfolio has broadened across psychiatry, migraine and Parkinson's, driving strong growth and raising its 2026 outlook.
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
AbbVie Inc. (ABBV) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
AbbVie Inc. (ABBV) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
AbbVie Maps Post-HUMIRA Growth With Apogee Deal, Immunology Pipeline
AbbVie NYSE: ABBV executives outlined a pipeline and business-development strategy centered on immunology, neuroscience, oncology and obesity, while highlighting plans to expand beyond the company's established SKYRIZI and RINVOQ franchises.
